Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 7/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.56 |
| ▸ | MAPT | P10636 | 9/20 | 0.56 |
| ▸ | RECQL | P46063 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 5/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | MTOR | P42345 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.56 |
| ▸ | BLM | P54132 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | THPO | P40225 | 2/20 | 0.56 |
| ▸ | APEX1 | P27695 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dioxethedrin SCHEMBL365011 | 0.98 | KDM4E (0.57) | ADRB2PTGS2OPRK1SLC6A3KDM4E | |
| SCHEMBL19361289 | 0.87 | ADRB2 (0.55) | ADRB2PTGS2OPRK1SLC6A3KDM4E | |
| SCHEMBL13158643 | 0.82 | TDP1 (0.51) | ADRB2PTGS2OPRK1SLC6A3KDM4E | |
| SCHEMBL10305082 | 0.82 | TDP1 (0.51) | ADRB2PTGS2OPRK1SLC6A3KDM4E | |
| Dioxifedrine SCHEMBL250137 | 0.80 | TDP1 (0.61) | ADRB2PTGS2OPRK1SLC6A3KDM4E | |
| SCHEMBL668000 | 0.80 | KDM4E (0.61) | ADRB2PTGS2OPRK1SLC6A3KDM4E | |
| SCHEMBL8006571 | 0.80 | TDP1 (0.54) | ADRB2PTGS2OPRK1SLC6A3KDM4E | |
| SCHEMBL27982685 | 0.79 | KDM4E (0.50) | ADRB2PTGS2OPRK1SLC6A3KDM4E | |
| Dioxifedrine SCHEMBL364347 | 0.79 | KDM4E (0.62) | ADRB2PTGS2OPRK1SLC6A3KDM4E | |
| SCHEMBL10763030 | 0.78 | TDP1 (0.54) | ADRB2PTGS2OPRK1SLC6A3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 797 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398729-A1 | Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | US | claimed |
| US-20190046471-A1 | Methods and Compositions for the Treatment of Steatosis-Associated Disorders | DUKE UNIVERSITY | 2019-02-14 | — | — | US | claimed |
| EP-3344337-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CYTOPPLASMIC GLYCOGEN STORAGE DISORDERS | Duke University (US) | 2018-07-11 | — | — | EP | claimed |
| CN-108025477-A | Polymer products and their preparation | 新加坡保健服务集团 | 2018-05-11 | — | — | CN | claimed |
| WO-2017049157-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF STEATOSIS-ASSOCIATED DISORDERS | DUKE UNIVERSITY (US) | 2017-03-23 | — | — | WO | claimed |
| WO-2017049161-A1 | ACID ALPHA-GLUCOSIDASE AND A β-2 AGONIST FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDER | DUKE UNIVERSITY (US) | 2017-03-23 | — | — | WO | claimed |
| WO-2017040647-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CYTOPPLASMIC GLYCOGEN STORAGE DISORDERS | DUKE UNIVERSITY (US) | 2017-03-09 | — | — | WO | claimed |
| US-8506935-B2 | Respiratory drug condensation aerosols and methods of making and using them | ALEXZA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | claimed |
| EP-1808169-B1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTEOTECH INC (US) | 2012-05-30 | — | — | EP | claimed |
| US-20120029085-A1 | STABILIZATION OF QUINOL COMPOSITION SUCH AS CATECHOLAMINE DRUGS | MACKAY JON (US) | 2012-02-02 | — | — | US | claimed |
| EP-1169294-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-01-09 | — | — | EP | claimed |
| US-20010047032-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTAMED, INC. | 2001-11-29 | — | — | US | claimed |
| WO-2001049281-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES | PROTEOTECH, INC. (US) | 2001-07-12 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| WO-2001012584-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2001-02-22 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061537-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047032-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | SNCA, PARK7, HTT | ADRB2 252/4885PTGS2 2788/4885OPRK1 695/4885 |
| US-20120029085-A1 | STABILIZATION OF QUINOL COMPOSITION SUCH AS CATECHOLAMINE DRUGS | ADRA2C, ADRB2, ADRB1 | ADRB2 2/4885PTGS2 502/4885OPRK1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.